Ching-Chun Li
Overview
Explore the profile of Ching-Chun Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chang Y, Tsai H, Chen Y, Li C, Huang C, Chen P, et al.
J Oncol
. 2023 Jan;
2023:2439128.
PMID: 36644232
Aims: An adjuvant oxaliplatin-based regimen is the standard of care for patients with stage III colorectal cancer (CRC). Few reports have compared the clinicopathological features and oncological outcomes of such...
12.
Tsai H, Tsai Y, Chen Y, Huang C, Chen P, Li C, et al.
Aging (Albany NY)
. 2022 Aug;
14(16):6668-6688.
PMID: 35997665
Angiogenesis and antiapoptosis effects are the major factors influencing malignancy progression. Hypoxia induces multiple mechanisms involving microRNA (miRNA) activity. Vascular endothelial growth factor (VEGF) is correlated with angiogenesis. An antiapoptotic...
13.
Huang C, Tsai H, Chen Y, Huang C, Li C, Su W, et al.
Front Oncol
. 2022 Aug;
12:889658.
PMID: 35936676
Colorectal cancer (CRC) is a global public health concern because of its high prevalence and mortality. Although radiotherapy is a key method for treating CRC, radioresistance is an obstacle to...
14.
Tsai H, Chen P, Chen Y, Li C, Chang T, Su W, et al.
J Int Med Res
. 2022 Jul;
50(7):3000605221110697.
PMID: 35822291
Objective: The polymorphism reduces enzymatic activity, which may increase the risk of severe toxicity in patients who receive standard-dose irinotecan, such as severe neutropenia and diarrhea. This real-world study assessed...
15.
Su W, Tsai Y, Tsai H, Chang T, Yin T, Huang C, et al.
Curr Issues Mol Biol
. 2022 Jun;
44(4):1552-1563.
PMID: 35723364
Personalized treatments based on the genetic profiles of tumors can simultaneously optimize efficacy and minimize toxicity, which is beneficial for improving patient outcomes. This study aimed to integrate gene alterations...
16.
Yip K, Tsai T, Yang I, Miao Z, Chen Y, Li C, et al.
Biomedicines
. 2022 May;
10(5).
PMID: 35625692
Studies have demonstrated that metformin has antitumor effects in addition to therapeutic effects on hyperglycemia; however, few studies have explored the effects of metformin in chemotherapy. Therefore, we hypothesized that...
17.
Li C, Chang T, Chen Y, Tsai H, Huang C, Su W, et al.
Cancer Manag Res
. 2022 May;
14:1541-1549.
PMID: 35498511
Background: The prognosis of metastatic colorectal cancer (mCRC) depends on the metastatic site and systemic therapy regimen. Peritoneal metastases are associated with a relatively unfavorable prognosis among patients with mCRC....
18.
Shi H, Chen Y, Huang C, Li C, Su W, Chang T, et al.
Front Oncol
. 2022 Apr;
12:756078.
PMID: 35359363
Objective: Patients with metastatic colorectal cancer (mCRC) had oncological benefits with irinotecan dose escalation of FOLFIRI regimen combined with bevacizumab according to genotypes in our previous study. In the current...
19.
Li C, Yeh Y, Chen Y, Su W, Chang T, Tsai H, et al.
J Oncol
. 2022 Mar;
2022:3719241.
PMID: 35345514
Background: The safety and efficacy of gastrectomy for locally advanced gastric cancer (LAGC) following neoadjuvant therapy have gained increasing attention. In this article, we present our preliminary treatment results and...
20.
Tsai H, Chen Y, Yin T, Su W, Chen P, Chang T, et al.
Oncol Res
. 2022 Feb;
29(1):47-61.
PMID: 35177165
() polymorphism plays a crucial role in the increased susceptibility and toxicity of patients to irinotecan. This retrospective, observational study compared the clinical outcomes and adverse events (AEs) in wild-type...